Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer (PRESOV)
Assessment of the Effect of a Co-treatment With GnRH Analogs on the Ovarian Reserve in Adolescents and Young Women Treated With Alkylating Agents for Cancer
Sponsor: Assistance Publique - Hôpitaux de Paris
This PHASE2/PHASE3 trial investigates Cancer and Ewing Sarcoma and is currently ongoing. Assistance Publique - Hôpitaux de Paris leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 5 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2018 — Jan 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique - Hôpitaux de Paris
For direct contact, visit the study record on ClinicalTrials.gov .